Phase II trial of bisantrene in non-small cell lung cancer

Thomas P. Miller, Frederick R. Ahmann, Cindy Mackel, Bernard R. Greenberg, David S. Alberts

Research output: Contribution to journalArticlepeer-review


Eighteen evaluable patients with non-small cell lung cancer (NSCLC) were treated with bisantrene at a dose of 200 mg/m2 once a week for 3 consecutive weeks. Courses of treatment were repeated every 4 weeks. This dose schedule caused leukopenia (< 3,500 cells/ μl) in all patients. There were no objective responses in 18 patients. Bisantrene in this myelosuppressive dose schedule did not have significant activity in patients with NSCLC.

Original languageEnglish (US)
Pages (from-to)393-395
Number of pages3
JournalInvestigational New Drugs
Issue number4
StatePublished - Dec 1985


  • bisantrene
  • non-small cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Phase II trial of bisantrene in non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this